{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United Kingdom Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/gb/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/gb/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from United Kingdom, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:f3d626ca39f60de91fbfb44f882a67b8ae9cb9a1777739f44f8b212e2ccb1a0a", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNd0QwNnpoblYyVXluNVVYOU9rRGlSYUZEZDdoRWdacHBaRzZYTGtBU1lyVTZMb0Ywdy12VWg0ZF9yd19jX3QtbF9CNno0OU5DT1JKZE1LYjF0ejFId3EtR054b0ZNM3pxWVdxMkU3aHBPdk5ac3JNcGJVZTVKa2FJRy0tNVdTNHRuaVRGZGJleHVUVmpVajNIRjdkeG15VzFKZGZTd0xiN3ZqTEhqajN4WmNZVDBEYkRManRHcFpuelpVRUNqMFZNa3JhdW9YQnJndVgweGlXMzBtOVJjLTBSMEh0VjlERnhsNVE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNd0QwNnpoblYyVXluNVVYOU9rRGlSYUZEZDdoRWdacHBaRzZYTGtBU1lyVTZMb0Ywdy12VWg0ZF9yd19jX3QtbF9CNno0OU5DT1JKZE1LYjF0ejFId3EtR054b0ZNM3pxWVdxMkU3aHBPdk5ac3JNcGJVZTVKa2FJRy0tNVdTNHRuaVRGZGJleHVUVmpVajNIRjdkeG15VzFKZGZTd0xiN3ZqTEhqajN4WmNZVDBEYkRManRHcFpuelpVRUNqMFZNa3JhdW9YQnJndVgweGlXMzBtOVJjLTBSMEh0VjlERnhsNVE?oc=5", "title": "Aptamer Group (APTA) Issues 12.9 Million Shares and Grants 863.8 Million Options to Directors Amid Growth Phase", "content_text": "Aptamer Group (APTA) Issues 12.9 Million Shares and Grants 863.8 Million Options to Directors Amid Growth Phase", "date_published": "2026-08-14T06:01:20+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Market update", "APTA"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "APTA", "name": "Aptamer Group PLC", "sentiment_url": "https://sharemaestro.com/sentiment/90ce0233-9577-40e4-ab9d-10e1eedad5e3/"}]}}, {"id": "source:a1f8a31dbb0c21cb7a11e769baa5a77754496b677e017c291dc29a9edc9c6505", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE4ySlF1VDcxOFFVX180SEtKYjNWbi1FN3FkRFJIVVRSa1M3VS1nVVh0bWVkUVgzcU9yMXlaclVfcVQxUjNMRUdrQ3J2ZzN3ODFPcVRMTmsyMy0xaW83OXBEdVJxbU1QLTV0OGxETnJ6cHo4RFE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE4ySlF1VDcxOFFVX180SEtKYjNWbi1FN3FkRFJIVVRSa1M3VS1nVVh0bWVkUVgzcU9yMXlaclVfcVQxUjNMRUdrQ3J2ZzN3ODFPcVRMTmsyMy0xaW83OXBEdVJxbU1QLTV0OGxETnJ6cHo4RFE?oc=5", "title": "Thalia Therapeutics PLC Revenue Breakdown \u2013 LSE:THAT", "content_text": "Thalia Therapeutics PLC Revenue Breakdown \u2013 LSE:THAT", "date_published": "2026-08-14T01:46:45+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "THAT"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "THAT", "name": "Thalia Therapeutics Plc", "sentiment_url": "https://sharemaestro.com/sentiment/c28ab7d4-d7c3-411b-9d99-17587fd08379/"}]}}, {"id": "source:6bfe3f44f42620b45b830e2b3995ad9250148b9fcb1902b2eff7e40613c4ad6c", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPNVhXSXZsUEx0NjZjTFIxUEtoTHdDbXl1ZFJiY2tuYVhQdU82ZWRMMGJtTl9iSlVlaW90N1hyTjFKbHhCQ1VkYnFpaUdKU2JtdVhBS1JXczBYbkFTZmFleGEyTWRBY1FPTVZoV3VjM0l3a3lyeWZxa1FBUnpXWHZnSEVrck9hdU9KSm9Vay0yblQtcDFXdDYw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPNVhXSXZsUEx0NjZjTFIxUEtoTHdDbXl1ZFJiY2tuYVhQdU82ZWRMMGJtTl9iSlVlaW90N1hyTjFKbHhCQ1VkYnFpaUdKU2JtdVhBS1JXczBYbkFTZmFleGEyTWRBY1FPTVZoV3VjM0l3a3lyeWZxa1FBUnpXWHZnSEVrck9hdU9KSm9Vay0yblQtcDFXdDYw?oc=5", "title": "CRISM Therapeutics Advances Towards Patient Recruitment for Phase II Glioblastoma Trial", "content_text": "CRISM Therapeutics Advances Towards Patient Recruitment for Phase II Glioblastoma Trial", "date_published": "2026-08-13T06:58:51+00:00", "authors": [{"name": "Market source"}], "tags": ["Market update", "CRTX"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRTX", "name": "CRISM Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/09a765a6-ba21-4f46-b556-bc1faac157b2/"}]}}, {"id": "source:d01bbdaca66ddba7a047e7e9d87b8d587dd399f5265446281fdeeba65e5a43cb", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPXzhjUnYtVEljSWJFek84Zi12MWhsZjN5bXY4ajlmei1OLWUzVmZ0a2d3MDNFUXpkZU5XcFVqQzB1VzIzNkgxS1F4ZUl3cEs2VzJ0Vmo1anNkRmZrVjR0NXJiRWVOZ1RIcEdKMzNUNGlHamV0RHpVaVJTUUt0bmtpY0ZOdFpNLWNoZmRCMUR2TjJTekgxcFVEV05jVmlMZ3R0MkF3ekpCMURmcGJ1R25rTzFqQUFVR2RGTnJnV2wzZ2Y?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPXzhjUnYtVEljSWJFek84Zi12MWhsZjN5bXY4ajlmei1OLWUzVmZ0a2d3MDNFUXpkZU5XcFVqQzB1VzIzNkgxS1F4ZUl3cEs2VzJ0Vmo1anNkRmZrVjR0NXJiRWVOZ1RIcEdKMzNUNGlHamV0RHpVaVJTUUt0bmtpY0ZOdFpNLWNoZmRCMUR2TjJTekgxcFVEV05jVmlMZ3R0MkF3ekpCMURmcGJ1R25rTzFqQUFVR2RGTnJnV2wzZ2Y?oc=5", "title": "CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial", "content_text": "CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial", "date_published": "2026-08-13T06:31:08+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "CRTX"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRTX", "name": "CRISM Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/09a765a6-ba21-4f46-b556-bc1faac157b2/"}]}}, {"id": "source:b0df2e90a675c2a8c2f2312c1b42fe63db8f4efa732a07995b0f067868fef3b0", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNbE1jT2ZRSjQ5NVVmdm8yYjNTVGNnZVhFazRrc3NkQUF0cG1razF5UVRaSTNxRzUtM0FHb3hIZjY3YlgyRW9zdUxFX1hVZnVLOUVKX25NV2plcnpQYllmSnNCUm5wRlFod08ycFZ5Z0lSSlJ3STZGMnhYampzV25jUHVNT2ZBczgwUVNXNVFkVWN0RnF2YUxtVm9DalV6UmpfOEk5STNFdF96eWE3bGtDX3Y0WC1DUlVDbFFMbXE3dzU0dXBWZ21kRmc0Q0MzdTNabWxwYXpKY3lfRkF1bDFJ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNbE1jT2ZRSjQ5NVVmdm8yYjNTVGNnZVhFazRrc3NkQUF0cG1razF5UVRaSTNxRzUtM0FHb3hIZjY3YlgyRW9zdUxFX1hVZnVLOUVKX25NV2plcnpQYllmSnNCUm5wRlFod08ycFZ5Z0lSSlJ3STZGMnhYampzV25jUHVNT2ZBczgwUVNXNVFkVWN0RnF2YUxtVm9DalV6UmpfOEk5STNFdF96eWE3bGtDX3Y0WC1DUlVDbFFMbXE3dzU0dXBWZ21kRmc0Q0MzdTNabWxwYXpKY3lfRkF1bDFJ?oc=5", "title": "Futura Medical Shares Surge as European Clearance for Eroxon Intense Lands", "content_text": "Futura Medical Shares Surge as European Clearance for Eroxon Intense Lands", "date_published": "2026-08-11T16:51:45+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "FUM"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FUM", "name": "Futura Medical plc", "sentiment_url": "https://sharemaestro.com/sentiment/b3eeed30-3af9-43d2-aebd-eddaeeff825d/"}]}}, {"id": "source:03fe5d7562749316b63337f2ad5b861e4084fe6968d98bf7f9d3a74ec36ac3f7", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOdlhfVUcwbUhwaDMzbzZvQ2FsSzc1YlYyRk5TUlZ3VUNJRVFzVlZVWHhWb1dENEZpSWlwbzloWWl5ckNXRmxDaVhUWldFeWdMVXRmYTRPVmNtVmJHbGJ3Tm40UFRUWTcxZnZuMlJWWmFqdjJZUmVwMXg2NVRWSmlHWUtLcUt2SW9LVy1icmsya1hSdXhxdllBbVA5LVFOZExNckV4clA0NEJKcUdUSzloalNkb3JKdkZfZ2s0eTNaSVdlUkllSFVLZmo0WHh2Q1BYMHVJdUhRbGZyX0V3NDhnTVkwME1JNk95YnNta01qQnFpVllsV3c?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOdlhfVUcwbUhwaDMzbzZvQ2FsSzc1YlYyRk5TUlZ3VUNJRVFzVlZVWHhWb1dENEZpSWlwbzloWWl5ckNXRmxDaVhUWldFeWdMVXRmYTRPVmNtVmJHbGJ3Tm40UFRUWTcxZnZuMlJWWmFqdjJZUmVwMXg2NVRWSmlHWUtLcUt2SW9LVy1icmsya1hSdXhxdllBbVA5LVFOZExNckV4clA0NEJKcUdUSzloalNkb3JKdkZfZ2s0eTNaSVdlUkllSFVLZmo0WHh2Q1BYMHVJdUhRbGZyX0V3NDhnTVkwME1JNk95YnNta01qQnFpVllsV3c?oc=5", "title": "Hemogenyx Pharmaceuticals (HEMO) Finalizes CAR-T Collaboration with Cellin Technologies for HG-CT-1 Therapy in Estonia", "content_text": "Hemogenyx Pharmaceuticals (HEMO) Finalizes CAR-T Collaboration with Cellin Technologies for HG-CT-1 Therapy in Estonia", "date_published": "2026-08-11T06:01:16+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Market update", "HEMO"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HEMO", "name": "Hemogenyx Pharmaceuticals Plc", "sentiment_url": "https://sharemaestro.com/sentiment/1220d327-fd14-4a2c-ba79-b24e39549f81/"}]}}, {"id": "source:cc872ba42f5b95729eae412bd8a196fa6e8cd249a5142d404c9cfbca96923091", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPX1cxNW9YcXl2NWR2UGp5Zjhxc0NOb2RSU0cyOUZFeHV2Mlp5WkJuR2xGOFJ6QnRibXVZOHktR3djS2dsSlNIcW44U2dSMnM1WEFwZ1dFdHVfdkNyV29OZ0J3QWpFY0tDT001Uks0eFc2LS1DUThaWmdZbU9sMk9nR2JRZVJvOUFpSndXU1lLaFJCZ0l0UVBiTm1sQmJPOThmZDdzeXpQRXFvT19PNVJQSkVpMmZMTUtLdG1YckFha0pyV3U4c1JNbW9Cd0NLbEtodS1N?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPX1cxNW9YcXl2NWR2UGp5Zjhxc0NOb2RSU0cyOUZFeHV2Mlp5WkJuR2xGOFJ6QnRibXVZOHktR3djS2dsSlNIcW44U2dSMnM1WEFwZ1dFdHVfdkNyV29OZ0J3QWpFY0tDT001Uks0eFc2LS1DUThaWmdZbU9sMk9nR2JRZVJvOUFpSndXU1lLaFJCZ0l0UVBiTm1sQmJPOThmZDdzeXpQRXFvT19PNVJQSkVpMmZMTUtLdG1YckFha0pyV3U4c1JNbW9Cd0NLbEtodS1N?oc=5", "title": "Coiled Therapeutics Shifts London Headquarters as Lead Cancer Drug Advances in Trials", "content_text": "Coiled Therapeutics Shifts London Headquarters as Lead Cancer Drug Advances in Trials", "date_published": "2026-08-10T11:05:12+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "COIL"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COIL", "name": "Coiled Therapeutics plc", "sentiment_url": "https://sharemaestro.com/sentiment/ec88c1b1-5420-4613-b412-eed427f14ea7/"}]}}, {"id": "source:9919ed09e15dde5aec66fb4d6f116e3545726538e83159b986881c266781e3ba", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTE5zN01LekI1NzBqdUJucVMxVE5ORmlQa3lDQi1fdDBiRXdBZ0hHdWpuNkZsWDdDdEhlTGotVVA1eWpDTUI3a0Y1dFhHSUY4NVBXVXZBYk53S0tfSS1RS3FMUUpHMzFNZG10Y1VTcWlnSEdFdC1rRGozU0VLaDFvR0hHUURudjhMakN1WGdUT3llU0FnaFdrZjN6N2IzaEt3aXVQeFdUOFVmNmdQSnNnSExnV2poUHgyZVJxb2tMQUJjQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTE5zN01LekI1NzBqdUJucVMxVE5ORmlQa3lDQi1fdDBiRXdBZ0hHdWpuNkZsWDdDdEhlTGotVVA1eWpDTUI3a0Y1dFhHSUY4NVBXVXZBYk53S0tfSS1RS3FMUUpHMzFNZG10Y1VTcWlnSEdFdC1rRGozU0VLaDFvR0hHUURudjhMakN1WGdUT3llU0FnaFdrZjN6N2IzaEt3aXVQeFdUOFVmNmdQSnNnSExnV2poUHgyZVJxb2tMQUJjQQ?oc=5", "title": "Top UK Penny Stocks to Explore in August: Poolbeg Pharma (LSE:POLB) Leads the Watchlist", "content_text": "Top UK Penny Stocks to Explore in August: Poolbeg Pharma (LSE:POLB) Leads the Watchlist", "date_published": "2026-08-10T09:25:00+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Market update", "POLB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "POLB", "name": "Poolbeg Pharma PLC", "sentiment_url": "https://sharemaestro.com/sentiment/7abc821a-17ab-461e-baa3-1675cf3c88d6/"}]}}, {"id": "source:732e648d0f0de85d1e3286ff1e7e89675cabff8b556811c216be3d1f3854b384", "url": "https://finance.yahoo.com/video/immupharma-valirx-tertiary-minerals-caledonia-075214482.html", "external_url": "https://finance.yahoo.com/video/immupharma-valirx-tertiary-minerals-caledonia-075214482.html", "title": "ImmuPharma, ValiRx, Tertiary Minerals, Caledonia Mining, Sintana Energy - Small Cap Snapshot", "content_text": "ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for its cancer-killing peptide from subsidiary Cytolytix. It's targeting triple negative breast cancer and is in talks with a major pharma company. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) has drilled some strong copper and silver hits at its Mushima North project in Zambia. Lab results are due in the coming weeks, wit", "date_published": "2026-08-10T07:52:14+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IMM", "VAL"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMM", "name": "ImmuPharma plc", "sentiment_url": "https://sharemaestro.com/sentiment/59b37edd-e336-4665-992e-68d8ca6142c3/"}, {"symbol": "VAL", "name": "ValiRx plc", "sentiment_url": "https://sharemaestro.com/sentiment/a14b38a9-5f7b-46fc-b303-50dd77328cfa/"}]}}, {"id": "source:f40fbc4d030c88f2ded40b76576372e090800239d3da878f7a45e9166e221277", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPcTdGS2R5SlVVb1IxcUdRd0JqZ296ZEZDVjY5UnNVRWpqb2RocjdRNDU4MFBySVRDZWV0UHZSSHkyclBtUWJFN2YzRVkxQ0tqZ1lSaTU2aEp2WTllSWV0N3dkOWtTQ2xUaWQtMGFNX1dMYTRRRkNwNW9TWDJVMFAzRTQ3MTMtOGpLekFoSDVaMUxBVUdOVHQxUnhIbVI?oc=5", "external_url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPcTdGS2R5SlVVb1IxcUdRd0JqZ296ZEZDVjY5UnNVRWpqb2RocjdRNDU4MFBySVRDZWV0UHZSSHkyclBtUWJFN2YzRVkxQ0tqZ1lSaTU2aEp2WTllSWV0N3dkOWtTQ2xUaWQtMGFNX1dMYTRRRkNwNW9TWDJVMFAzRTQ3MTMtOGpLekFoSDVaMUxBVUdOVHQxUnhIbVI?oc=5", "title": "Price to earnings forward of IXICO Plc \u2013 LSE:IXI", "content_text": "Price to earnings forward of IXICO Plc \u2013 LSE:IXI", "date_published": "2026-08-09T06:50:37+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "IXI"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IXI", "name": "IXICO plc", "sentiment_url": "https://sharemaestro.com/sentiment/0afe7433-489d-471a-a627-da7be1dc6d47/"}]}}, {"id": "source:2a4e05895aad51a76f54fb492126a19c8a70a059c0387879221837515e0ac3aa", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5yajFueVV2UEgzaVNyVlZoV2NOMWFnWDI0SW5VS25rdC1SZmk2YUxTSWstQjNQeXFUcFdPQ3c1eENQREpOWkNwY2RHZXA2eTNmQVNOc3l1TC1QcDN6WWJpZ3Z3cmVrOGhnVkl6WWZNcG9Tdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5yajFueVV2UEgzaVNyVlZoV2NOMWFnWDI0SW5VS25rdC1SZmk2YUxTSWstQjNQeXFUcFdPQ3c1eENQREpOWkNwY2RHZXA2eTNmQVNOc3l1TC1QcDN6WWJpZ3Z3cmVrOGhnVkl6WWZNcG9Tdw?oc=5", "title": "ImmuPharma plc Revenue Breakdown \u2013 LSE:IMM", "content_text": "ImmuPharma plc Revenue Breakdown \u2013 LSE:IMM", "date_published": "2026-08-08T20:37:34+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "IMM"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMM", "name": "ImmuPharma plc", "sentiment_url": "https://sharemaestro.com/sentiment/59b37edd-e336-4665-992e-68d8ca6142c3/"}]}}, {"id": "source:7aa993b35be1fac61cd5021bed9cabb943f7cf46bd6581853c89d60758ed6488", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPa01tM0RIX1N5b1FyaDk4UFF3bnFvTnYzSndfLTRDNFZSUHZOd1J2UE5fcVdzaU1hRkhTaHctZEJITFBPZEI1YUo5VThVNWNrTTIxdjFkcXhhOVBlVjRhYWxUSXN3dHRXMzNMNVVZbVVzekdEcms4Y0U1eUlKUXZScFhiWmlVNGpTY1RESTJPVWhyOWFBbF85SkhFcXJicEtULUgtUE0xb0x1OHg2NndKMjBvLXg0Y21GTUFISDFJQ25uLXE1bXlNOFhDWG1hdEE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPa01tM0RIX1N5b1FyaDk4UFF3bnFvTnYzSndfLTRDNFZSUHZOd1J2UE5fcVdzaU1hRkhTaHctZEJITFBPZEI1YUo5VThVNWNrTTIxdjFkcXhhOVBlVjRhYWxUSXN3dHRXMzNMNVVZbVVzekdEcms4Y0U1eUlKUXZScFhiWmlVNGpTY1RESTJPVWhyOWFBbF85SkhFcXJicEtULUgtUE0xb0x1OHg2NndKMjBvLXg0Y21GTUFISDFJQ25uLXE1bXlNOFhDWG1hdEE?oc=5", "title": "UK's Oxford Biomedica tumbles after annual revenue forecast cut", "content_text": "UK's Oxford Biomedica tumbles after annual revenue forecast cut", "date_published": "2026-08-07T13:43:25+00:00", "authors": [{"name": "Reuters"}], "tags": ["Earnings", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:a81421e0558e357447edc99db6f3d4e0ca429c7c7e587a214d2e723363c22cc7", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPc1Z1b0R2RzNoUExEc3UxTVBFd1g0cHRoU2NqbnV6aTduazFNR0FrcWJSZFE1NzR6QkRGdTcyMG9aRGxiZUVkd0FlNHF3ME9xTmpxYkFSQnhJWmJMbVZCNmtIZERYY0s2Sm5xVjV3RzJoeFpYMmpkY2YtY2k4ZWRfclVnc2FVLTh2YTE1UDZQNnFVNkpaTXNpWEpYNjFId1FCdThZVDAtLVRUb191WlJCSWdvUlAwNzNlTjBWdzBLUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPc1Z1b0R2RzNoUExEc3UxTVBFd1g0cHRoU2NqbnV6aTduazFNR0FrcWJSZFE1NzR6QkRGdTcyMG9aRGxiZUVkd0FlNHF3ME9xTmpxYkFSQnhJWmJMbVZCNmtIZERYY0s2Sm5xVjV3RzJoeFpYMmpkY2YtY2k4ZWRfclVnc2FVLTh2YTE1UDZQNnFVNkpaTXNpWEpYNjFId1FCdThZVDAtLVRUb191WlJCSWdvUlAwNzNlTjBWdzBLUQ?oc=5", "title": "Oxford BioMedica shares fall after delays impact revenue expectations", "content_text": "Oxford BioMedica shares fall after delays impact revenue expectations", "date_published": "2026-08-07T10:18:15+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Earnings", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:da06ec4a61d3704a5181f7b8fffea4f59ec1916eebbbfd474def79f55e2b35ca", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTTRmb2xES056c21MWWtlSVFOeTJpSDNpYmxpM0xSUTlRTnRGVmx0U3RuTkdHTGlQTjhRZXgxMlUxbVF4OFZsTjJ3WXJpLWJJSnppM3lRenk0TU4wOUJVSm44ZGhUSTg3QTRNLU5sdmVxbG4zOVZxcmp3b3ZmQmw4T29RNThtQlpDajhXYWlCenNuRkNGTmN6c3RzSHBhcjI2YmJtdGE0Y20tcExEVG1tQThYZ0tZd0FG?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTTRmb2xES056c21MWWtlSVFOeTJpSDNpYmxpM0xSUTlRTnRGVmx0U3RuTkdHTGlQTjhRZXgxMlUxbVF4OFZsTjJ3WXJpLWJJSnppM3lRenk0TU4wOUJVSm44ZGhUSTg3QTRNLU5sdmVxbG4zOVZxcmp3b3ZmQmw4T29RNThtQlpDajhXYWlCenNuRkNGTmN6c3RzSHBhcjI2YmJtdGE0Y20tcExEVG1tQThYZ0tZd0FG?oc=5", "title": "WINNERS & LOSERS: Goodwin jumps; Oxford BioMedica trims revenue view", "content_text": "WINNERS & LOSERS: Goodwin jumps; Oxford BioMedica trims revenue view", "date_published": "2026-08-07T09:21:52+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Earnings", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:57101df9264eac61469f79f130b0b5ba748ba76f1cb40a3bc017296e0a84ac0f", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNa3lJb0NMU21mRG83T1BPNmtuLTBQcEhOLWRMZENYWGNQUEE1a1B3cWZLVFM5VWJnMzkyMVR4U3FTYWN4bTFEVTBLcDI0V1lZNWcwcFJRTkp5ckk3R2I2WFV4M2lvRUY4bHJTZDRRWmR3NFp1Um43U01KZFdRQUxQMFBlSnFrT0pMYmNwcU1BMWVtUWVtSEYyRlhkUmNRSWRZSGlUSUl2VWNVZXV0aDN4Y29uWTBpUEpqbG5Sb0Y3OWNUd3pCb00tc0NjUTNRVXJhbUpGTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNa3lJb0NMU21mRG83T1BPNmtuLTBQcEhOLWRMZENYWGNQUEE1a1B3cWZLVFM5VWJnMzkyMVR4U3FTYWN4bTFEVTBLcDI0V1lZNWcwcFJRTkp5ckk3R2I2WFV4M2lvRUY4bHJTZDRRWmR3NFp1Um43U01KZFdRQUxQMFBlSnFrT0pMYmNwcU1BMWVtUWVtSEYyRlhkUmNRSWRZSGlUSUl2VWNVZXV0aDN4Y29uWTBpUEpqbG5Sb0Y3OWNUd3pCb00tc0NjUTNRVXJhbUpGTQ?oc=5", "title": "Oxford BioMedica tanks 24% after earnings alert; brokers take stock", "content_text": "Oxford BioMedica tanks 24% after earnings alert; brokers take stock", "date_published": "2026-08-07T08:03:00+00:00", "authors": [{"name": "Proactive Investors"}], "tags": ["Earnings", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:722fe53b120318b2a094299c5e6ab23d96b695664e6e7929cd251f7238de08a8", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPYTlmektEdXpFUGxETkppVE1ET29yNEVGVzBsYlJYSTFNWC1aSm15S0l0VDlfWm8zVGJmQjFZYXhWa1hONXY4SmNQUXJOSTdIb3BwMzRxbm5xZ0pmZWNGTlVqZ2ZraV9lVGhDam4yS25iNHFHeVJ1QVdzM2YtNEVXaV9SNXExYm8tZVFTNFZJLTZocTFHWDZvcWJpY0tmX3Ez?oc=5", "external_url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPYTlmektEdXpFUGxETkppVE1ET29yNEVGVzBsYlJYSTFNWC1aSm15S0l0VDlfWm8zVGJmQjFZYXhWa1hONXY4SmNQUXJOSTdIb3BwMzRxbm5xZ0pmZWNGTlVqZ2ZraV9lVGhDam4yS25iNHFHeVJ1QVdzM2YtNEVXaV9SNXExYm8tZVFTNFZJLTZocTFHWDZvcWJpY0tmX3Ez?oc=5", "title": "Oxford Biomedica Shares Slump on Deep FY2026 Revenue Downgrade", "content_text": "Oxford Biomedica Shares Slump on Deep FY2026 Revenue Downgrade", "date_published": "2026-08-07T07:43:51+00:00", "authors": [{"name": "AskTraders"}], "tags": ["Earnings", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:9984a003cedcbe2cef27725fa8c64a76f3e49f8f9d664123b860e2608b6310da", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQN0xkeElNYnV5RENWa0ZZZGV5a2xwMTFDT2F2OHVVSWpJQUptXy0tZTFUSWNRTHFSUmlVVXF0UjV4c1MtWk5jOGliMXZ4ekx0YmdmWndzNWpUcGQxZDdNSUM2TmxXR0NtUFRpWWVQM2xrZUhSMGQ0X3V0RnNYQnd0VlhXN2pTY1VibndNR1BuNA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQN0xkeElNYnV5RENWa0ZZZGV5a2xwMTFDT2F2OHVVSWpJQUptXy0tZTFUSWNRTHFSUmlVVXF0UjV4c1MtWk5jOGliMXZ4ekx0YmdmWndzNWpUcGQxZDdNSUM2TmxXR0NtUFRpWWVQM2xrZUhSMGQ0X3V0RnNYQnd0VlhXN2pTY1VibndNR1BuNA?oc=5", "title": "Oxford Biomedica Lowers 2026 Guidance Despite Strong Client Growth", "content_text": "Oxford Biomedica Lowers 2026 Guidance Despite Strong Client Growth", "date_published": "2026-08-07T07:32:19+00:00", "authors": [{"name": "Market source"}], "tags": ["Guidance", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:d5a106a893d0c780fa103ad61f92eb1c5c78a99033d379c74cf83c6d7f1deaa5", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOQWhNcEVlYkZYczdpbjFuTmo2UVdxU1NTMUVvVkVya3VRejVhNTBiTm85RzBkMnBXWC1kZFIyeFVBR2x2Vy1zY2l2aHBYcjF2Z0V1TWd2aEstYXVmX2VHLXBOV2h3M0YzS0pvbTlFaTB6RHl6eGxlanhpeEp6d0VSaVNjT1J5U2ROV1E3TUNqNktrbEU4ZkNRNHh6YUl6VzJMNVhuVGFB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOQWhNcEVlYkZYczdpbjFuTmo2UVdxU1NTMUVvVkVya3VRejVhNTBiTm85RzBkMnBXWC1kZFIyeFVBR2x2Vy1zY2l2aHBYcjF2Z0V1TWd2aEstYXVmX2VHLXBOV2h3M0YzS0pvbTlFaTB6RHl6eGxlanhpeEp6d0VSaVNjT1J5U2ROV1E3TUNqNktrbEU4ZkNRNHh6YUl6VzJMNVhuVGFB?oc=5", "title": "Oxford Nanopore (LSE:ONT) Reflects the Genomics Growth Theme", "content_text": "Oxford Nanopore (LSE:ONT) Reflects the Genomics Growth Theme", "date_published": "2026-08-06T12:48:00+00:00", "authors": [{"name": "kalkinemedia.com"}], "tags": ["Market update", "ONT"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ONT", "name": "Oxford Nanopore Technologies plc", "sentiment_url": "https://sharemaestro.com/sentiment/c1d5de20-bb9c-478b-b643-c7dc8ae9ec99/"}]}}, {"id": "source:e9c6df63214276c32faffe0c00e6629c6bd9b68b62658d9da715b864a900b628", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOOERtN3BMZllxb1c1eVlaMFpqeWJnekhJczZvZzQzRmdsd211c0hIcUtOOVZEMzVkOHJqZU1HTm45a01MWmZvZHlWMTBIM2VlOVEzWVBsaFBMR1VvNDF6X3l4czdJdjVndEwycFJSOExHX3VEUVJsRjR5TjBjcjBDdnBHNTZFUnhWSFhNVzNST1JkeUZYdlEtSGZTeTFUT1diQ1YtcU1XSUVUcE03ajlkeXlSZFY?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOOERtN3BMZllxb1c1eVlaMFpqeWJnekhJczZvZzQzRmdsd211c0hIcUtOOVZEMzVkOHJqZU1HTm45a01MWmZvZHlWMTBIM2VlOVEzWVBsaFBMR1VvNDF6X3l4czdJdjVndEwycFJSOExHX3VEUVJsRjR5TjBjcjBDdnBHNTZFUnhWSFhNVzNST1JkeUZYdlEtSGZTeTFUT1diQ1YtcU1XSUVUcE03ajlkeXlSZFY?oc=5", "title": "Ondine Biomedical (LSE:OBI) Makes Data Quality the Next Penny-Stock Catalyst", "content_text": "Ondine Biomedical (LSE:OBI) Makes Data Quality the Next Penny-Stock Catalyst", "date_published": "2026-08-06T12:26:00+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Market update", "OBI"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OBI", "name": "Ondine Biomedical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6fb19c52-3b6b-46f5-864a-2a70b6d9c457/"}]}}, {"id": "source:850729a7208fbf09413d48493a6268ea7366fef98728e9b613618cee1f7b8858", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTXpGVWN2M2trb2N3dTBwQjRBbXNJOXh5NWpfNjFzUG5LOEx1NTd6M3VKc0RpaWkzY0xQaTlfZW0ySTRWT1hJOXBibHFzRllBMHo1ZlZVSTZEWF83S2s2REhPS0s2cUtqRmJ4dThKM2dKbEtxQTNPQ0VKdU5MMkNhZ01YSFA4MnlEUEg3V0FNeVM3RXFGNm1jZkFjaWYxdzRSSTRnbUZGaHI?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTXpGVWN2M2trb2N3dTBwQjRBbXNJOXh5NWpfNjFzUG5LOEx1NTd6M3VKc0RpaWkzY0xQaTlfZW0ySTRWT1hJOXBibHFzRllBMHo1ZlZVSTZEWF83S2s2REhPS0s2cUtqRmJ4dThKM2dKbEtxQTNPQ0VKdU5MMkNhZ01YSFA4MnlEUEg3V0FNeVM3RXFGNm1jZkFjaWYxdzRSSTRnbUZGaHI?oc=5", "title": "Enterprise value to revenue forward of CRISM Therapeutics Corporation \u2013 LSE:CRTX", "content_text": "Enterprise value to revenue forward of CRISM Therapeutics Corporation \u2013 LSE:CRTX", "date_published": "2026-08-05T22:50:09+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "CRTX"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRTX", "name": "CRISM Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/09a765a6-ba21-4f46-b556-bc1faac157b2/"}]}}, {"id": "source:7f56446477d92aad33fab9e00eb724dc82278d0385dad3c890798a086e3bbc0a", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOeXQ5bGttNl9RWEpRbGx2R0UzYmxNamdCaVBfZndXbTY2NGdQNXFLT0hpWFd0dE4wQ0Y5Y2hOYk81dmZreUFKeVl3Y1UwZmxNMHQzblk3cWZXSEYxYmxlS3Y4T1FEeDVTbzFoZlk0eGJUdVA0TkZnSUdQTkljb1g3WEdqVWhuNk5neG1fTUxpT3o2Z01LWHpNZ00xeUI1WmY2NHM2dWNGQTZXZXJWdU5Gdlp4b2hGMjRTTjZYVW9kV0k2RVZjZUE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOeXQ5bGttNl9RWEpRbGx2R0UzYmxNamdCaVBfZndXbTY2NGdQNXFLT0hpWFd0dE4wQ0Y5Y2hOYk81dmZreUFKeVl3Y1UwZmxNMHQzblk3cWZXSEYxYmxlS3Y4T1FEeDVTbzFoZlk0eGJUdVA0TkZnSUdQTkljb1g3WEdqVWhuNk5neG1fTUxpT3o2Z01LWHpNZ00xeUI1WmY2NHM2dWNGQTZXZXJWdU5Gdlp4b2hGMjRTTjZYVW9kV0k2RVZjZUE?oc=5", "title": "Fusion Antibodies Secures Australian Acceptance for Antibody Library Patent", "content_text": "Fusion Antibodies Secures Australian Acceptance for Antibody Library Patent", "date_published": "2026-08-05T07:00:00+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "FAB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FAB", "name": "Fusion Antibodies plc", "sentiment_url": "https://sharemaestro.com/sentiment/e6fad22a-650f-4d1f-8ebf-42a6331e97cd/"}]}}, {"id": "source:65a783edec53d06595ad5da08fe73937b56d2c1581bdc95acbe76c38985af0b5", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNd0drclBuT1hycE9ubHRIVFVzay0za1RzN2h1WEtHTmhDNElvWFRrUkhQYTBIQVk0TEowaW5zTjBWUkdfZjN6azE5V3I5bzZ2dkg3a2ZQNElzRVFnQmhYV0IzYkZHS05kUXNxbUNJUk5UNjNJQi1kSUVYeE51UnZJdlluQ3JhZnFLbHZoWDNfeGJobU0wWWdkRGlhNTI?oc=5", "external_url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNd0drclBuT1hycE9ubHRIVFVzay0za1RzN2h1WEtHTmhDNElvWFRrUkhQYTBIQVk0TEowaW5zTjBWUkdfZjN6azE5V3I5bzZ2dkg3a2ZQNElzRVFnQmhYV0IzYkZHS05kUXNxbUNJUk5UNjNJQi1kSUVYeE51UnZJdlluQ3JhZnFLbHZoWDNfeGJobU0wWWdkRGlhNTI?oc=5", "title": "Price to earnings forward of Ondine Biomedical, Inc. \u2013 LSE:OBI", "content_text": "Price to earnings forward of Ondine Biomedical, Inc. \u2013 LSE:OBI", "date_published": "2026-08-04T12:58:45+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "OBI"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OBI", "name": "Ondine Biomedical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6fb19c52-3b6b-46f5-864a-2a70b6d9c457/"}]}}, {"id": "source:15c08a44f72c71a24a2fc6a5d7b77afd5b295561a0723e7726863eb000d31832", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQZ3RnaGNKU0pEekJoWWRVcWFrUHVwVU9mWUxPaW95RTJPQkhOUEpLM0daTlJzN0VIMHc5SkZDbENIdzRpSDJlVk13clZuWVgtcHN0ZXZJNWJIM2NWam4wY2xTNm16THpBV1VwOHQxT29wTUkyYjgtUmRkVWxLOHBIaUVRTGZSZWtqalVHVVl3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQZ3RnaGNKU0pEekJoWWRVcWFrUHVwVU9mWUxPaW95RTJPQkhOUEpLM0daTlJzN0VIMHc5SkZDbENIdzRpSDJlVk13clZuWVgtcHN0ZXZJNWJIM2NWam4wY2xTNm16THpBV1VwOHQxT29wTUkyYjgtUmRkVWxLOHBIaUVRTGZSZWtqalVHVVl3?oc=5", "title": "BSF Enterprise Shares Rises 47% on T-Rex Leather expansion", "content_text": "BSF Enterprise Shares Rises 47% on T-Rex Leather expansion", "date_published": "2026-08-03T08:41:33+00:00", "authors": [{"name": "Share Talk"}], "tags": ["Market update", "BSFA"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSFA", "name": "BSF Enterprise Plc", "sentiment_url": "https://sharemaestro.com/sentiment/171311db-1960-476e-9986-f23ed513228a/"}]}}, {"id": "source:b9ebf61deb736f491aa6504639e53a9a43c791f106c704f1cd999d7881eb3b97", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxORXc3TDJKeVlwSUt3d0pFLVJLY2NXOWp6ZlNIRkk2cTM1b2QxeVpxSHQ3TkhOazlzMDNWVHh4MDZWa0phN3R0Z2xjM05TdzdsN3dZVXVPT0FDeTQyZ2QzYkhWN1pNWU03WHpWVEphazNhS1RHR1IwajA4bjZIU0p0b1AtOThaRUhmQzctRGxrUFRDLVJ3aF9XdXlIUHFZNFRwTlUwNHRoY05qXzhqeXFKUHN0VURyaU9nc3ZRcklXYVR0UWh1?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxORXc3TDJKeVlwSUt3d0pFLVJLY2NXOWp6ZlNIRkk2cTM1b2QxeVpxSHQ3TkhOazlzMDNWVHh4MDZWa0phN3R0Z2xjM05TdzdsN3dZVXVPT0FDeTQyZ2QzYkhWN1pNWU03WHpWVEphazNhS1RHR1IwajA4bjZIU0p0b1AtOThaRUhmQzctRGxrUFRDLVJ3aF9XdXlIUHFZNFRwTlUwNHRoY05qXzhqeXFKUHN0VURyaU9nc3ZRcklXYVR0UWh1?oc=5", "title": "Why Genflow Biosciences (LSE:GENF) Is Drawing Fresh Attention in Longevity Research", "content_text": "Why Genflow Biosciences (LSE:GENF) Is Drawing Fresh Attention in Longevity Research", "date_published": "2026-08-03T07:11:00+00:00", "authors": [{"name": "kalkinemedia.com"}], "tags": ["Market update", "GENF"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GENF", "name": "Genflow Biosciences plc", "sentiment_url": "https://sharemaestro.com/sentiment/58fbeadf-36df-4bee-b1a6-fb9a51481ba7/"}]}}, {"id": "source:bec8b93b84124a6828f54005649fe8790231ccbca983344d41501c3662937791", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFByaVN1bm1PTThJeWFkbGJIcnpwOWNFcGJsZHVLbmVGOUlxVDloaHkxYkZob185SFhMNm9iN0g2V3BDTTdmbnVpUlRPdU1iQ25yV3VWd1F6eTFCZmpOZXZaM3VLTFBGYVdSOGIyeTdGQUZpWjg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFByaVN1bm1PTThJeWFkbGJIcnpwOWNFcGJsZHVLbmVGOUlxVDloaHkxYkZob185SFhMNm9iN0g2V3BDTTdmbnVpUlRPdU1iQ25yV3VWd1F6eTFCZmpOZXZaM3VLTFBGYVdSOGIyeTdGQUZpWjg?oc=5", "title": "Avacta Group PLC Revenue Breakdown \u2013 LSE:AVCT", "content_text": "Avacta Group PLC Revenue Breakdown \u2013 LSE:AVCT", "date_published": "2026-08-01T05:37:49+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "AVCT"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AVCT", "name": "Avacta Group Plc", "sentiment_url": "https://sharemaestro.com/sentiment/6c180d20-8da0-4454-85c4-602c9b980498/"}]}}, {"id": "source:a55dc77dcc7f33738dba46d942590f7357e485a829c106498dc204eaa4ce8d19", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE10UkZwMGRoaTgzVTJzSU00NE8zRVB1MjY3YXRBV1diZi1iQzNfYkw2bDhaTEVoV0EwRWU5Sk1TZDhHQXo2azM2YlF3Um9CZEZOYzdTZjJxVjduQ1NsRDFUeE1ERXFQVW5jUmRJQ1AxMUpPeE0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE10UkZwMGRoaTgzVTJzSU00NE8zRVB1MjY3YXRBV1diZi1iQzNfYkw2bDhaTEVoV0EwRWU5Sk1TZDhHQXo2azM2YlF3Um9CZEZOYzdTZjJxVjduQ1NsRDFUeE1ERXFQVW5jUmRJQ1AxMUpPeE0?oc=5", "title": "Scancell Holdings Plc Revenue Breakdown \u2013 LSE:SCLP", "content_text": "Scancell Holdings Plc Revenue Breakdown \u2013 LSE:SCLP", "date_published": "2026-07-31T22:33:53+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "SCLP"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SCLP", "name": "Scancell Holdings plc", "sentiment_url": "https://sharemaestro.com/sentiment/91b90cf7-eff9-429e-8365-4b7d09e6821c/"}]}}, {"id": "source:5ba54d8d75d41ab2dd845f880bdfd44cd0a7d2d1466d2e87a0f1e9bad9af13a3", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbXZkbVpwQ1BDRlYwTnhVc09oa2MyUHVkMFVPMG9SMVNkQ1U1Q0xoV28zaWlmQ3NtREJ1b3pwYTIxcXNRdGs4V0Q4aGRVenVGNGtnNWsybkV5ZnZnc2xTOEROWW9OVXlXazB6VkFIc1h3Z1o5VjhrY3FwbVJaYkJQRkFEamF3R1JlelB4YTZPTUszVXh6X3UzWVo5UkVmaEwzZ3FtNTJnaV93VTlXVWFKT25iTm1sZTlXeU53NkQ5TjV6YjdL?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbXZkbVpwQ1BDRlYwTnhVc09oa2MyUHVkMFVPMG9SMVNkQ1U1Q0xoV28zaWlmQ3NtREJ1b3pwYTIxcXNRdGs4V0Q4aGRVenVGNGtnNWsybkV5ZnZnc2xTOEROWW9OVXlXazB6VkFIc1h3Z1o5VjhrY3FwbVJaYkJQRkFEamF3R1JlelB4YTZPTUszVXh6X3UzWVo5UkVmaEwzZ3FtNTJnaV93VTlXVWFKT25iTm1sZTlXeU53NkQ5TjV6YjdL?oc=5", "title": "Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances", "content_text": "Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances", "date_published": "2026-07-31T10:32:39+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "THAT"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "THAT", "name": "Thalia Therapeutics Plc", "sentiment_url": "https://sharemaestro.com/sentiment/c28ab7d4-d7c3-411b-9d99-17587fd08379/"}]}}, {"id": "source:c1012edaac26fdd1189e0ecee720841620c8f991ba8980460e86a25266467480", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNOHc4c3BFalNGcl8tQWR2dmpheHFQd1BFZzZGOUhEZmZvbHpZRTFaUVhRdTRlTGRFamxyUlZ4bXNpS3YzUEliOVNtSUZ3WXB5YXZwUmhNR2FiTDRKWkZjRjF0S0I0SGxQRzhjVjFQaG1veDB6UWlGUzFfbWtaT0VPSWU4bTlET00yeDhkMmV1WWlvRldidWJpd2UtMlNiMHNmZ01IQmZKRGl3ZmU4UEpKMw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNOHc4c3BFalNGcl8tQWR2dmpheHFQd1BFZzZGOUhEZmZvbHpZRTFaUVhRdTRlTGRFamxyUlZ4bXNpS3YzUEliOVNtSUZ3WXB5YXZwUmhNR2FiTDRKWkZjRjF0S0I0SGxQRzhjVjFQaG1veDB6UWlGUzFfbWtaT0VPSWU4bTlET00yeDhkMmV1WWlvRldidWJpd2UtMlNiMHNmZ01IQmZKRGl3ZmU4UEpKMw?oc=5", "title": "Are IQE (LSE:IQE) And Aptamer (LSE:APTA) Exposed To The Tech Sentiment Reset?", "content_text": "Are IQE (LSE:IQE) And Aptamer (LSE:APTA) Exposed To The Tech Sentiment Reset?", "date_published": "2026-07-31T07:00:00+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Market update", "APTA"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "APTA", "name": "Aptamer Group PLC", "sentiment_url": "https://sharemaestro.com/sentiment/90ce0233-9577-40e4-ab9d-10e1eedad5e3/"}]}}, {"id": "source:f8e43627630cdb130eabd5ded8d64557242af48c740c47724cc7f3e525cc6230", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPdWxlMHlnNUJfcUNCdjNiSWs2OEpKcEotYldfRVlMY2tFTnY4X3h6MEk0NWE5WUtBdDhDdU40MEJCVkt1dGlGenVZU3NZa3A3ME9TWTBpVmFHd3pLVU1sb2c3eHV6c0ZoQXBvMm54bE1ZVktpVmJrLTBJS0UteW1TVklqbjI0VW9KYzFwYjNjTGZ4R2tVeFBCeTF6YnhiaUJoUF9hZ0tXZi1fZ01IQUtNWlRIN2ZhVUtUeUlhTWNpZktEeFlRNWJ0RnFZRDNlZGNUNUVGLVJhQ04?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPdWxlMHlnNUJfcUNCdjNiSWs2OEpKcEotYldfRVlMY2tFTnY4X3h6MEk0NWE5WUtBdDhDdU40MEJCVkt1dGlGenVZU3NZa3A3ME9TWTBpVmFHd3pLVU1sb2c3eHV6c0ZoQXBvMm54bE1ZVktpVmJrLTBJS0UteW1TVklqbjI0VW9KYzFwYjNjTGZ4R2tVeFBCeTF6YnhiaUJoUF9hZ0tXZi1fZ01IQUtNWlRIN2ZhVUtUeUlhTWNpZktEeFlRNWJ0RnFZRDNlZGNUNUVGLVJhQ04?oc=5", "title": "Futura Medical (FUM) Gains EEA and UK Approval for Eroxon\u00ae Intense Erectile Dysfunction Treatment", "content_text": "Futura Medical (FUM) Gains EEA and UK Approval for Eroxon\u00ae Intense Erectile Dysfunction Treatment", "date_published": "2026-07-31T06:01:33+00:00", "authors": [{"name": "kalkinemedia.com"}], "tags": ["Regulatory and legal", "FUM"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FUM", "name": "Futura Medical plc", "sentiment_url": "https://sharemaestro.com/sentiment/b3eeed30-3af9-43d2-aebd-eddaeeff825d/"}]}}, {"id": "source:ac02c7f6faa2cccde1a6e9ccd3f271fe137922ff9a0a2d0046533df197781e82", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE90YWpRcXB3eDVRc1ZrY2ExdEdUdWVfLWExazcwaDliRmVwNFNOYkVHS3VrMzZhQTY0dGlyTHI0ejRWT3M4UzhxQlV2N01IcWo3TUhNR0JiWjdRX0dfR3Uxdm1GbzNnR0hmMGlsTVZXZjhOdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMickFVX3lxTE90YWpRcXB3eDVRc1ZrY2ExdEdUdWVfLWExazcwaDliRmVwNFNOYkVHS3VrMzZhQTY0dGlyTHI0ejRWT3M4UzhxQlV2N01IcWo3TUhNR0JiWjdRX0dfR3Uxdm1GbzNnR0hmMGlsTVZXZjhOdw?oc=5", "title": "ValiRx PLC Revenue Breakdown \u2013 LSE:VAL", "content_text": "ValiRx PLC Revenue Breakdown \u2013 LSE:VAL", "date_published": "2026-07-30T21:43:24+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "VAL"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VAL", "name": "ValiRx plc", "sentiment_url": "https://sharemaestro.com/sentiment/a14b38a9-5f7b-46fc-b303-50dd77328cfa/"}]}}, {"id": "source:42e830b53f3d97791c155975c24daca4c53a840758df578a7a0578b2671d5178", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONXNia25FcldHVmdGZ0FwMjZpU3hOTlVYY2VGZS1Sc0F3bkhmdE1OYXk5TzBDS0RUaXRZZDdkWERQaHY5OUFVLWJwLTVOa2JPQ3JpNTVaUmNJQnIxdEl3d3FhZ2hFWGtkbjZ4Zk1lTFh2am5oX1RNSFk5S2kwVTk2RXBHdVV2cDBteXBDUjZ1dVlUVkFsdXFVd3RmWHY4cGZ3VzhNWDk4aWFEeVREOGdpMlM2dXZLalk?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONXNia25FcldHVmdGZ0FwMjZpU3hOTlVYY2VGZS1Sc0F3bkhmdE1OYXk5TzBDS0RUaXRZZDdkWERQaHY5OUFVLWJwLTVOa2JPQ3JpNTVaUmNJQnIxdEl3d3FhZ2hFWGtkbjZ4Zk1lTFh2am5oX1RNSFk5S2kwVTk2RXBHdVV2cDBteXBDUjZ1dVlUVkFsdXFVd3RmWHY4cGZ3VzhNWDk4aWFEeVREOGdpMlM2dXZLalk?oc=5", "title": "Growth Stocks: Why Oxford Nanopore (LSE:ONT) Remains in Focus After Its Update?", "content_text": "Growth Stocks: Why Oxford Nanopore (LSE:ONT) Remains in Focus After Its Update?", "date_published": "2026-07-29T07:00:00+00:00", "authors": [{"name": "kalkinemedia.com"}], "tags": ["Market update", "ONT"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ONT", "name": "Oxford Nanopore Technologies plc", "sentiment_url": "https://sharemaestro.com/sentiment/c1d5de20-bb9c-478b-b643-c7dc8ae9ec99/"}]}}, {"id": "source:d2cce72648690333a410ae47b176d3fe9882c4fee30092ed3e656987d7de1a11", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9NMFBhSDVkMWNhaHNJQ0JPX3dXaTYyOUc4SXVpR2VkVmFxRGFMMWxLTUFQZEwxX1R1SlE5YVUtUlI4MGszeEZIOHJFOHFiU3psZjJTNkJiMGxJY1ZPVFR6aGdna0lkVEdZS1NNaWZTYVZiVlU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9NMFBhSDVkMWNhaHNJQ0JPX3dXaTYyOUc4SXVpR2VkVmFxRGFMMWxLTUFQZEwxX1R1SlE5YVUtUlI4MGszeEZIOHJFOHFiU3psZjJTNkJiMGxJY1ZPVFR6aGdna0lkVEdZS1NNaWZTYVZiVlU?oc=5", "title": "BSF Enterprise PLC Revenue Breakdown \u2013 LSE:BSFA", "content_text": "BSF Enterprise PLC Revenue Breakdown \u2013 LSE:BSFA", "date_published": "2026-07-27T19:06:39+00:00", "authors": [{"name": "tradingview.com"}], "tags": ["Earnings", "BSFA"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSFA", "name": "BSF Enterprise Plc", "sentiment_url": "https://sharemaestro.com/sentiment/171311db-1960-476e-9986-f23ed513228a/"}]}}, {"id": "source:237e42a504d5da0eadecf58b510b43589abc591cfa8452bc2625cab302c9244c", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5jQnRxWHZyUk1QTW5vbml1S0VMTmlTSldVblhpMnZpUUc3RXZKaXlLMDk2aV9XcFIxZ3BKMm1INVN6UmppbWZiblVWbEhadGdrTlctWU15d1pvZWhsanhXVUxDU0pMT2lNU1RkblYtbXNTQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5jQnRxWHZyUk1QTW5vbml1S0VMTmlTSldVblhpMnZpUUc3RXZKaXlLMDk2aV9XcFIxZ3BKMm1INVN6UmppbWZiblVWbEhadGdrTlctWU15d1pvZWhsanhXVUxDU0pMT2lNU1RkblYtbXNTQQ?oc=5", "title": "Oxford Nanopore Technologies Plc Revenue Breakdown \u2013 LSE:ONT", "content_text": "Oxford Nanopore Technologies Plc Revenue Breakdown \u2013 LSE:ONT", "date_published": "2026-07-27T08:42:39+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "ONT"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ONT", "name": "Oxford Nanopore Technologies plc", "sentiment_url": "https://sharemaestro.com/sentiment/c1d5de20-bb9c-478b-b643-c7dc8ae9ec99/"}]}}, {"id": "source:1611f2c1f97f71e2fb4d624d6cbbba95815a8c5702b8b088a65143eace67c2e6", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE5qRm1VemY4Z2l3OVA4V2c4dkYtODRYTV93QmhjUG1yOGhpSWVnQVlxaHZxUXZVMDNRRzhoNUYzS0hHdy1JZ3duam1wTGJfZmphb1kwcTYzTmRoei01SUtzR2JVcEZyNVdhSjdCLVd0c3BvZ2M?oc=5", "external_url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE5qRm1VemY4Z2l3OVA4V2c4dkYtODRYTV93QmhjUG1yOGhpSWVnQVlxaHZxUXZVMDNRRzhoNUYzS0hHdy1JZ3duam1wTGJfZmphb1kwcTYzTmRoei01SUtzR2JVcEZyNVdhSjdCLVd0c3BvZ2M?oc=5", "title": "Faron Pharmaceuticals Oy Revenue Breakdown \u2013 LSE:FARN", "content_text": "Faron Pharmaceuticals Oy Revenue Breakdown \u2013 LSE:FARN", "date_published": "2026-07-26T15:13:54+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "FARN"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FARN", "name": "Faron Pharmaceuticals Oy", "sentiment_url": "https://sharemaestro.com/sentiment/3900f9da-6e1e-436f-8a60-f81954041085/"}]}}, {"id": "source:7ca5b8f1fa046c43e5521a11765efdd4b4f2df06941a04ef0dedf570fb53ea4e", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTFAyM191MXRlOHJSdlc3QjFsMWRIUGxCZFBqb3hrUl9pUE9UQlp3WW5rYXdQWkxnelZrR0x1eWdQUkoxak5sNUZ2bGJodlY0OE41dWtzRnpjelpGOHI3Y05WamNBZWpHWWpSbHJldm1PNFRQQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMickFVX3lxTFAyM191MXRlOHJSdlc3QjFsMWRIUGxCZFBqb3hrUl9pUE9UQlp3WW5rYXdQWkxnelZrR0x1eWdQUkoxak5sNUZ2bGJodlY0OE41dWtzRnpjelpGOHI3Y05WamNBZWpHWWpSbHJldm1PNFRQQQ?oc=5", "title": "Futura Medical plc Revenue Breakdown \u2013 LSE:FUM", "content_text": "Futura Medical plc Revenue Breakdown \u2013 LSE:FUM", "date_published": "2026-07-25T19:17:14+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "FUM"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FUM", "name": "Futura Medical plc", "sentiment_url": "https://sharemaestro.com/sentiment/b3eeed30-3af9-43d2-aebd-eddaeeff825d/"}]}}, {"id": "source:1069abc5dd7e09eab5e9a41bc62e061d0ad0565ddeeb0a502b4a2823d9f96dfa", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFBnZ1ZiQ0hBTjRwZlhQY0JoN2dXZUgyS29sZkQxVVp0WjJKMkdkT0lLbmxlQlJrY2ZSYnMzaV81eWRWZlFfRkFERlFyVTFUeWJZOVVhYlFOQlc2THNFa1pyUFZPQllHeXRoUjBGM2k3UzRKWGM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFBnZ1ZiQ0hBTjRwZlhQY0JoN2dXZUgyS29sZkQxVVp0WjJKMkdkT0lLbmxlQlJrY2ZSYnMzaV81eWRWZlFfRkFERlFyVTFUeWJZOVVhYlFOQlc2THNFa1pyUFZPQllHeXRoUjBGM2k3UzRKWGM?oc=5", "title": "CRISM Therapeutics Corporation Revenue Breakdown \u2013 LSE:CRTX", "content_text": "CRISM Therapeutics Corporation Revenue Breakdown \u2013 LSE:CRTX", "date_published": "2026-07-25T19:15:40+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "CRTX"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRTX", "name": "CRISM Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/09a765a6-ba21-4f46-b556-bc1faac157b2/"}]}}, {"id": "source:16f6068b2fe7072c4affe02026cdea2d5e14559275278db87cde9f3c1780ebf1", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing", "content_text": "Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing", "date_published": "2026-07-23T07:00:00+00:00", "authors": [{"name": "The Manila Times"}], "tags": ["Deals and strategy", "SCLP"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SCLP", "name": "Scancell Holdings plc", "sentiment_url": "https://sharemaestro.com/sentiment/91b90cf7-eff9-429e-8365-4b7d09e6821c/"}]}}, {"id": "source:3b5b139abf78f45790de29859292d7ae6fa7b191ac79248b654fcfca4ebfae92", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNR1ZUS0lTNmhUd0tkbVJraUdneU9iTEZZMFl5ZmU3akhaTVNoaVdaOWNjaFdjNXJRTnlXTk9oNUNtQXQ4QlB2Mk9ueE5yN1JjamNnM1l2Z2ljczhPOWFfVHZlVzhmS25jN3FGZ1VGVWp2RmprS3ZOSmVCVWFwb202WHNJNjZhTm5mOW54dlptd1lrV2xPdWRoaQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNR1ZUS0lTNmhUd0tkbVJraUdneU9iTEZZMFl5ZmU3akhaTVNoaVdaOWNjaFdjNXJRTnlXTk9oNUNtQXQ4QlB2Mk9ueE5yN1JjamNnM1l2Z2ljczhPOWFfVHZlVzhmS25jN3FGZ1VGVWp2RmprS3ZOSmVCVWFwb202WHNJNjZhTm5mOW54dlptd1lrV2xPdWRoaQ?oc=5", "title": "AIM Market Roundup: Sunrise Resources, Futura Medical, Plexus", "content_text": "AIM Market Roundup: Sunrise Resources, Futura Medical, Plexus", "date_published": "2026-07-20T07:00:00+00:00", "authors": [{"name": "The Armchair Trader"}], "tags": ["Market update", "FUM"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FUM", "name": "Futura Medical plc", "sentiment_url": "https://sharemaestro.com/sentiment/b3eeed30-3af9-43d2-aebd-eddaeeff825d/"}]}}, {"id": "source:3fdc311bfce59d5355704b2cb5c1c9ead54568f3515fd4a38dadb9202baa3386", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBJbTFxQjcwX2E0ZmdFMTlvUk9iUnM5ZjBmM1IzVEc0NmpJTlNTbkIxc1VULTNNV253dktSdE5jZGVid1Y1Rm81d2tZenhNQ3FO?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBJbTFxQjcwX2E0ZmdFMTlvUk9iUnM5ZjBmM1IzVEc0NmpJTlNTbkIxc1VULTNNV253dktSdE5jZGVid1Y1Rm81d2tZenhNQ3FO?oc=5", "title": "Nuformix plc (LSE: NFX) Share Price, NFX Stock News, NFX Share Price & Updates", "content_text": "Nuformix plc (LSE: NFX) Share Price, NFX Stock News, NFX Share Price & Updates", "date_published": "2026-07-17T07:00:00+00:00", "authors": [{"name": "Kalkine"}], "tags": ["Market update", "NFX"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NFX", "name": "Nuformix plc", "sentiment_url": "https://sharemaestro.com/sentiment/2bfb4a4a-12e2-4bbf-b253-1482880be5e4/"}]}}, {"id": "source:fbd17ca8df77740d2d9d066e39d6b52f98042293cbd92c0412fefa66c81512c5", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQYzNUNGhHMnRNRzFKZGR1Z2o4b3oyWFhlYngxekR3djZaclRhM2FHSVdnOFhiVmlWdFlzYXdtVkt1VDFLemJHOExZN0dnY0tDLWhrU1ZEeExVRUdsZ2p2ZEkta2xkczBkOGx6VXZfaHVHOV9Zbi1pdFg5ZnU5Q0VSdHBMcXlpY0xrU0VfMkEtdEl2RFhBbTNfM2FVZHNwc1ZoWW80NFh3QVFIaWV6Tkp1cjRtanJNTU5hVzltNVdlbFpIZGZxMXFNUl82b1dDRkFFMHZWUE9MSjM3VEpRb0NzYS1kNXYxbHp0OFdvd1dhRVpmaWc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQYzNUNGhHMnRNRzFKZGR1Z2o4b3oyWFhlYngxekR3djZaclRhM2FHSVdnOFhiVmlWdFlzYXdtVkt1VDFLemJHOExZN0dnY0tDLWhrU1ZEeExVRUdsZ2p2ZEkta2xkczBkOGx6VXZfaHVHOV9Zbi1pdFg5ZnU5Q0VSdHBMcXlpY0xrU0VfMkEtdEl2RFhBbTNfM2FVZHNwc1ZoWW80NFh3QVFIaWV6Tkp1cjRtanJNTU5hVzltNVdlbFpIZGZxMXFNUl82b1dDRkFFMHZWUE9MSjM3VEpRb0NzYS1kNXYxbHp0OFdvd1dhRVpmaWc?oc=5", "title": "Thalia Therapeutics eyes clinical-stage transition as shareholders vote on Sanmirna deal", "content_text": "Thalia Therapeutics eyes clinical-stage transition as shareholders vote on Sanmirna deal", "date_published": "2026-07-17T06:28:00+00:00", "authors": [{"name": "Proactive Investors"}], "tags": ["Deals and strategy", "THAT"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "THAT", "name": "Thalia Therapeutics Plc", "sentiment_url": "https://sharemaestro.com/sentiment/c28ab7d4-d7c3-411b-9d99-17587fd08379/"}]}}, {"id": "source:238f3f39e0cefc47498d60d8175809c465930cd381dce2b4ca3096da6ba2b816", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOTldYSTYyUUQ3SlhVdTZOR2dVV2hGOHFOUUhKSC1sR1o0bUJMOVdYSDFYd19KejI2Njd1RkJWcUktYkFkbWkxb0hPZFViZkRwRWJxRVV3NmdxSEgtcHFzd1hGeUM5Y0FiejJra0J6al8xdFFKcFBlZkxOSjJoTExGdF8zNFNGTkZPTnd1d0pB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOTldYSTYyUUQ3SlhVdTZOR2dVV2hGOHFOUUhKSC1sR1o0bUJMOVdYSDFYd19KejI2Njd1RkJWcUktYkFkbWkxb0hPZFViZkRwRWJxRVV3NmdxSEgtcHFzd1hGeUM5Y0FiejJra0J6al8xdFFKcFBlZkxOSjJoTExGdF8zNFNGTkZPTnd1d0pB?oc=5", "title": "Aptamer Group Reports Revenue Growth as Licensing Strategy Builds Momentum (APTA)", "content_text": "Aptamer Group Reports Revenue Growth as Licensing Strategy Builds Momentum (APTA)", "date_published": "2026-07-13T07:00:00+00:00", "authors": [{"name": "Market source"}], "tags": ["Earnings", "APTA"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "APTA", "name": "Aptamer Group PLC", "sentiment_url": "https://sharemaestro.com/sentiment/90ce0233-9577-40e4-ab9d-10e1eedad5e3/"}]}}, {"id": "source:44d3ac31222f6b06c52e6d9c2d963ea2746a3a22ed8fe5dbcd60e845739ac7ae", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNZ0hydDdUTUh6UldvT3VPU1UtSFJIZko3dHEwcEF6TDIwS1NrclFVWUptbDhtX0FKemZ6TGJSU1BEbnhmTHRqR1VBWjZ6RF91UFJJSjdZTkFLTXhDSVhrZWhScVVadnFucDRYdTVwQ1VOalJReTVyUHBINW1QREpwRFJIRFFMREtqbTNWaHoySWlaUDE1aG1kbHZCSWdKNlRNNXFUVUZ4WjBQdGFsbzM2NEtIS1g2RjBwUEs0MTBCQ1pmNjFNRWtOUzFwYw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNZ0hydDdUTUh6UldvT3VPU1UtSFJIZko3dHEwcEF6TDIwS1NrclFVWUptbDhtX0FKemZ6TGJSU1BEbnhmTHRqR1VBWjZ6RF91UFJJSjdZTkFLTXhDSVhrZWhScVVadnFucDRYdTVwQ1VOalJReTVyUHBINW1QREpwRFJIRFFMREtqbTNWaHoySWlaUDE1aG1kbHZCSWdKNlRNNXFUVUZ4WjBQdGFsbzM2NEtIS1g2RjBwUEs0MTBCQ1pmNjFNRWtOUzFwYw?oc=5", "title": "REG - Genus PLC - FY26 Trading Update \u2013 Ahead of expectations", "content_text": "REG - Genus PLC - FY26 Trading Update \u2013 Ahead of expectations", "date_published": "2026-07-13T07:00:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "GNS"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GNS", "name": "Genus plc", "sentiment_url": "https://sharemaestro.com/sentiment/741e8c05-fe2a-4a91-a424-8def18473c74/"}]}}, {"id": "source:926148f9f72524a1c1e025cb2c821c7a7ecfe5c1c9822a282fc0b819da1cd2d0", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Discover UK Penny Stocks: Poolbeg Pharma And Two More Top Picks", "content_text": "Discover UK Penny Stocks: Poolbeg Pharma And Two More Top Picks", "date_published": "2026-07-10T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "POLB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "POLB", "name": "Poolbeg Pharma PLC", "sentiment_url": "https://sharemaestro.com/sentiment/7abc821a-17ab-461e-baa3-1675cf3c88d6/"}]}}, {"id": "source:d57a110de2d8743a0357b474151830468b77575ab1dfd0b7767f7da933d82bb7", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOeDhMb2Y5MUcwbUNqS0tCVHY3b1pJN2pISWJEWXNUMjhtSUI3djZ6ajhtVWl4ZGFzNU1qRjF1clRtNnptZkFRaml6d3hQdmIyMUYwS3owUmdzc2pQSk9sSmhydHRsXzREem1zMHpCMXpGX3M2TG05V0NMNHBDZl9ZZ0lEcjFTVFFhX2RsakRESnBrRHRGREJyNjRiT3RMSnFKTVM0Z25rbWZxZDkyS0xqY18wdFdJeE1FSlhuOUZ0ZUtlSTQxaTM4TA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOeDhMb2Y5MUcwbUNqS0tCVHY3b1pJN2pISWJEWXNUMjhtSUI3djZ6ajhtVWl4ZGFzNU1qRjF1clRtNnptZkFRaml6d3hQdmIyMUYwS3owUmdzc2pQSk9sSmhydHRsXzREem1zMHpCMXpGX3M2TG05V0NMNHBDZl9ZZ0lEcjFTVFFhX2RsakRESnBrRHRGREJyNjRiT3RMSnFKTVM0Z25rbWZxZDkyS0xqY18wdFdJeE1FSlhuOUZ0ZUtlSTQxaTM4TA?oc=5", "title": "REG - Oxford Biomedica PLC M&G PLC - Holding(s) in Company", "content_text": "REG - Oxford Biomedica PLC M&G PLC - Holding(s) in Company", "date_published": "2026-07-08T07:00:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:1f4ed3e2b0833a8d000efe82abbd20a89c966c6a095f373df3509785c8260d68", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQNlQ5cXM0VHVGalFRWnZVS1dRcHVwZ0owNFlYWUNkWVJyWDZQUWQ3czJWQ1hDTTZvTUlOSm94NEZmeE5XdnNLMzhxOUg2aVJteElPVlhha01sVGhMQlcwbzBZWHh5M21YVVV5QU52SHFzV0k4eFJJaGF6QVA2TGZoMUxMYjJjTmJGMEktZk9GSUlrSFdHNi1DY1hPZDNHWlQyYkhCcnl4MEY3TEwwU2pWckdnQ3UydG1HNUZ4UFdMQzlDSGRVZnp4NmdoaDBnWGhqTTBEblhnYUpwekFReVpkWVlFbWU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQNlQ5cXM0VHVGalFRWnZVS1dRcHVwZ0owNFlYWUNkWVJyWDZQUWQ3czJWQ1hDTTZvTUlOSm94NEZmeE5XdnNLMzhxOUg2aVJteElPVlhha01sVGhMQlcwbzBZWHh5M21YVVV5QU52SHFzV0k4eFJJaGF6QVA2TGZoMUxMYjJjTmJGMEktZk9GSUlrSFdHNi1DY1hPZDNHWlQyYkhCcnl4MEY3TEwwU2pWckdnQ3UydG1HNUZ4UFdMQzlDSGRVZnp4NmdoaDBnWGhqTTBEblhnYUpwekFReVpkWVlFbWU?oc=5", "title": "REG - Coiled Therapeutics - Coiled Advances Next-Generation AO-252 Formulation", "content_text": "REG - Coiled Therapeutics - Coiled Advances Next-Generation AO-252 Formulation", "date_published": "2026-07-06T07:00:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "COIL"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COIL", "name": "Coiled Therapeutics plc", "sentiment_url": "https://sharemaestro.com/sentiment/ec88c1b1-5420-4613-b412-eed427f14ea7/"}]}}, {"id": "source:86a73897def2d8d173be43d66a632eeae46a352b7b5bddccf6fbed2c8aa136a0", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWFpua0FxMUVuV0pJem9kYmZfS1k0OFd1MFIyOFhQVW1CUEcxSXNVUFQ4QU5iSllKamZXSXZpbF92NU1nQWpWSVNJX2FGbzlETFkxV3JhSFkxSEpZeFhKTGxkMmxmN1NZcEtNVHdDWVZqaG9HbXJmTkE2X3p5aXFKTXdxNVdHNlUwU29MSDM5dlFoeXRfVGtVeHlxVEFpb2pxcy1wM2ZFZ2NiS2JwSkpWdFhHUjVzUkYxUlRV?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWFpua0FxMUVuV0pJem9kYmZfS1k0OFd1MFIyOFhQVW1CUEcxSXNVUFQ4QU5iSllKamZXSXZpbF92NU1nQWpWSVNJX2FGbzlETFkxV3JhSFkxSEpZeFhKTGxkMmxmN1NZcEtNVHdDWVZqaG9HbXJmTkE2X3p5aXFKTXdxNVdHNlUwU29MSDM5dlFoeXRfVGtVeHlxVEFpb2pxcy1wM2ZFZ2NiS2JwSkpWdFhHUjVzUkYxUlRV?oc=5", "title": "REG - CRISM Therapeutics - Holding(s) in Company", "content_text": "REG - CRISM Therapeutics - Holding(s) in Company", "date_published": "2026-07-02T07:00:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "CRTX"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRTX", "name": "CRISM Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/09a765a6-ba21-4f46-b556-bc1faac157b2/"}]}}, {"id": "source:195f6d8b6fc5854f9aed93c718d2d400c6b9a14bf145e63491027812bde4d44b", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPR1o0MkRpTjBWTk1LMWZnNGR6VHZSSlZIbExRSTl4TU1kNF9vZ29OcEU4X21BTmFCUWlpZE1mV2dzekdmLTJxWHpPV3hlcVlSblNlenNfWFR0Vk9OcWY5N0NhRE5UcnB6WjZ1Sm1hQU9pNkJRR1BLS2U0UDJqbnV3OHBGTUp1bi13eDQtblA4RWFMbXQtSnEwNGtB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPR1o0MkRpTjBWTk1LMWZnNGR6VHZSSlZIbExRSTl4TU1kNF9vZ29OcEU4X21BTmFCUWlpZE1mV2dzekdmLTJxWHpPV3hlcVlSblNlenNfWFR0Vk9OcWY5N0NhRE5UcnB6WjZ1Sm1hQU9pNkJRR1BLS2U0UDJqbnV3OHBGTUp1bi13eDQtblA4RWFMbXQtSnEwNGtB?oc=5", "title": "Price to sales forward of Poolbeg Pharma PLC \u2013 LSE:POLB", "content_text": "Price to sales forward of Poolbeg Pharma PLC \u2013 LSE:POLB", "date_published": "2026-07-02T01:20:11+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "POLB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "POLB", "name": "Poolbeg Pharma PLC", "sentiment_url": "https://sharemaestro.com/sentiment/7abc821a-17ab-461e-baa3-1675cf3c88d6/"}]}}, {"id": "source:161d21269427f4e04dd3f290e77b38515775479e333f68f1021f5f5003409a9a", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSEF5VUY0ZVZBbDExOThjLW1fV2tGZzlMUXRWa3U3ZWtUd2hjUk5zalFFZGt5MXNrZGVUZ0dCaWZkckN1c0lPNndDdzVFOXpsSFFJZHNiVXZ3RnR5dEtGcFoxcXpBem5YTlBKWTB1MG11QXdFTUZWTHpCUnMta05ndl8xVXROWGlDMThLRklTMjFMb2UzaGRaTmNJQzNhcHA2ZFRkcFAtNHMtVVdVaUJuaGNiNDlLSVJQT0E?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSEF5VUY0ZVZBbDExOThjLW1fV2tGZzlMUXRWa3U3ZWtUd2hjUk5zalFFZGt5MXNrZGVUZ0dCaWZkckN1c0lPNndDdzVFOXpsSFFJZHNiVXZ3RnR5dEtGcFoxcXpBem5YTlBKWTB1MG11QXdFTUZWTHpCUnMta05ndl8xVXROWGlDMThLRklTMjFMb2UzaGRaTmNJQzNhcHA2ZFRkcFAtNHMtVVdVaUJuaGNiNDlLSVJQT0E?oc=5", "title": "REG - Fusion Antibodies - Holding(s) in Company", "content_text": "REG - Fusion Antibodies - Holding(s) in Company", "date_published": "2026-07-01T07:00:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "FAB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FAB", "name": "Fusion Antibodies plc", "sentiment_url": "https://sharemaestro.com/sentiment/e6fad22a-650f-4d1f-8ebf-42a6331e97cd/"}]}}, {"id": "source:7597ea6e57d578604c709fba34ba9c1d98260c94f40e1713ed6d736e537492bc", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOc3RVYmRMb2NQRURBQ2V5SVZOZGU5TUZvVFlPZjU4aG5uY2pMMHJMSUd4ZlN3eHlBejQ2MnNveXoxSURpZ05XYW54NW44SkdoR2FPb2ZuRUlHbWh0OW1ydDRXRE9tM1B2a2JPcUFkSE9WeUVFLVFZWHBMUWY0R0RwOE80V3dqYkU2ZE9PUDhQcU5JbWpjcGo4Si14N2s?oc=5", "external_url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOc3RVYmRMb2NQRURBQ2V5SVZOZGU5TUZvVFlPZjU4aG5uY2pMMHJMSUd4ZlN3eHlBejQ2MnNveXoxSURpZ05XYW54NW44SkdoR2FPb2ZuRUlHbWh0OW1ydDRXRE9tM1B2a2JPcUFkSE9WeUVFLVFZWHBMUWY0R0RwOE80V3dqYkU2ZE9PUDhQcU5JbWpjcGo4Si14N2s?oc=5", "title": "Price to earnings forward of Oxford BioMedica plc \u2013 LSE:OXB", "content_text": "Price to earnings forward of Oxford BioMedica plc \u2013 LSE:OXB", "date_published": "2026-06-30T03:41:15+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "OXB"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OXB", "name": "Oxford Biomedica plc", "sentiment_url": "https://sharemaestro.com/sentiment/95def50f-c78f-4cc2-9794-e66d3b39f20d/"}]}}, {"id": "source:e6ab8e79bb497bc82dcd0c8576b70e51b03500c434e6425f623a7c46ffa29c61", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOck1va3ZIMDIyQVZKelQ1RkthRHRRUlg0d0pFZG50RHdQVHZ4N1FzQnV6VC1LQnlsSHRZU2FmVmtvbTRJU1Zlb1NUS0liMjBUQW9JTjZCVlM0VDBHOVRCc0hDc0s5T0NBSEdkY29LdmZLNWVvUnAtdGJfakNxZlJHeExnMUNyWG9xeHVjWkVtYUtGbGhYWURSamh3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOck1va3ZIMDIyQVZKelQ1RkthRHRRUlg0d0pFZG50RHdQVHZ4N1FzQnV6VC1LQnlsSHRZU2FmVmtvbTRJU1Zlb1NUS0liMjBUQW9JTjZCVlM0VDBHOVRCc0hDc0s5T0NBSEdkY29LdmZLNWVvUnAtdGJfakNxZlJHeExnMUNyWG9xeHVjWkVtYUtGbGhYWURSamh3?oc=5", "title": "Price to sales forward of HemoGenyx Pharmaceuticals Plc \u2013 LSE:HEMO", "content_text": "Price to sales forward of HemoGenyx Pharmaceuticals Plc \u2013 LSE:HEMO", "date_published": "2026-06-30T01:36:19+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "HEMO"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HEMO", "name": "Hemogenyx Pharmaceuticals Plc", "sentiment_url": "https://sharemaestro.com/sentiment/1220d327-fd14-4a2c-ba79-b24e39549f81/"}]}}]}